Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

davidclynes

David Clynes, a post-doctoral scientist in Richard Gibbons' lab, has successfully been awarded a grant through the CNRS-Oxford Collaboration scheme.  The scheme aims to facilitate the development of new collaborations, between researchers at the two organisations.  David will use the funding to visit the Almouzni laboratory in Paris with the collaborative aim to study the dynamics of ATRX mediated histone deposition.

Of the award, David said 'this offers a very exciting opportunity to build collaborations between the WIMM and another world leading research organisation and using cutting edge techniques developed in the Almouzni laboratory, we are excited to enhance our understanding of the temporal dynamics of ATRX mediated histone deposition'.

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.